MA-FORRESTER
According to Forrester’s (Nasdaq: FORR) The Top 10 Emerging Technologies In 2024 report, generative AI (genAI) for visual content, genAI for language, TuringBots, and IoT security are the top emerging technologies that will deliver the most immediate ROI for businesses in 2024 and beyond.
With new technologies emerging seemingly every day, business and technology leaders need to time those investments based on value, risk, and potential payout timelines. Forrester organizes its top emerging technologies by benefit horizon to help with these decisions.
Emerging technologies that will offer significant benefits within the next two years:
- GenAI for visual content. Advanced machine learning models that generate images or video from text, audio, or video prompts, this technology will help firms generate visual content for marketing, experiences, and products.
- GenAI for language. GenAI for language is already delivering value in customer support and content creation but continues to advance at a blinding pace. It is accelerating many other technologies as it goes.
- TuringBots. Accelerated by advancements in genAI for language, these AI-powered software robots help developers build applications that deliver more than just code generation.
- IoT security. The proliferation of devices has led to an exponential explosion in security attacks, raising the importance of security for IoT devices. Vendors are competing and colliding in a rush to offer capabilities.
Midterm emerging technologies that will deliver benefits in the next two to five years:
- AI agents. The role of autonomous workplace assistants or AI agents has expanded beyond the back office and employee assistance to customer-facing automation. These AI agents will grow increasingly sophisticated to better understand and respond to nuance and context.
- Autonomous mobility. This technology will accelerate commercial and urban transportation ecosystem collaborations to orchestrate personalized mobility experiences for both customers and businesses.
- Edge intelligence. Advanced edge intelligence capabilities such as edge machine learning are still not yet common, even though many foundational elements like Apple foundation models are becoming available.
- Quantum security. This technology will overhaul security systems for on-premises and cloud compute, storage and network infrastructure, commercial off-the-shelf software, commercial software-as-a-service offerings, and in-house built software.
Emerging technologies that will take at least five more years to deliver tangible value for most firms and use cases:
- Extended reality (XR). Only 8% of US online adults own a virtual-reality headset, and just 16% have used an augmented-reality device or app. While XR is advancing in training and onboarding, companies are resisting investing in tools like these until they see broad adoption.
- Zero Trust edge (ZTE). ZTE technology has the potential to protect remote workers, retail outlets, and branch offices with embedded local security, but only a handful of true ZTE solutions exist today, and legacy devices add additional management complexity.
“Tech leaders must be able to identify the right use cases and quantify potential benefits, costs, and risks across multiple horizons,” says Brian Hopkins, Forrester VP, emerging tech portfolio. “They need to spread investments out, with shorter-term technologies delivering quick returns and longer-term bets requiring more effort, more foundational investment, and the capacity to manage more risk.”
Resources:
- Learn more about the top emerging technologies that will deliver ROI for enterprises.
- Read The Top 10 Emerging Technologies In 2024 report to gain insight into maturity trends, business value, important use cases, and risks associated with each technology (client access required).
- Register for a complimentary webinar that takes a deep dive into the 2024 list of emerging technologies and their use cases and benefits.
- Download Forrester’s complimentary guide for tech leaders to identify use cases and gain support for emerging technologies.
- Tech and data leaders can attend Forrester’s 2024 Technology & Innovation Summits in North America, EMEA, and Asia Pacific to learn how to align their IT strategy to their business goals to accelerate growth.
About Forrester
Forrester (Nasdaq: FORR) is one of the most influential research and advisory firms in the world. We help leaders across technology, customer experience, digital, marketing, sales, and product functions use customer obsession to accelerate growth. Through Forrester’s proprietary research, consulting, and events, leaders from around the globe are empowered to be bold at work — to navigate change and put their customers at the center of their leadership, strategy, and operations. Our unique insights are grounded in annual surveys of more than 700,000 consumers, business leaders, and technology leaders worldwide; rigorous and objective research methodologies, including Forrester Wave™ evaluations; more than 100 million real-time feedback votes; and the shared wisdom of our clients. To learn more, visit Forrester.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625049417/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
